The reduction in price target by Wells Fargo, a major financial institution, could lead to a negative short-term sentiment among investors, potentially causing a decrease in CRISPR Therapeutics' stock price. The Equal-Weight rating suggests that the analyst views the stock as adequately valued at its current price, but the lowered target indicates a reassessment of the stock's future growth potential or risk profile.